ASBP

Aspire Biopharma Holdings, Inc. (ASBP) Risks & Opportunities Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-09-01

Overall Score

Financial Distress Liquidity

Strong near-term liquidity with a current ratio of 7.99 and cash ratio of 7.22.

Balance sheet leverage appears minimal, with debt-to-equity and debt-to-capital both at 0.

Net current asset value remains positive at 11.68M, supporting downside protection.

Profitability Operating Risk

Gross margin is positive at 18.35%, showing the core product still generates some contribution.

EBITDA margin is 33.67%, but operating and net margins remain deeply negative.

Return on invested capital is -0.60%, indicating capital is not yet being deployed profitably.

Valuation Optionality

The stock screens cheap on book value, with price-to-book at 0.79.

Enterprise value is negative, which can create unusual valuation optionality if cash remains intact.

Price-to-sales of 10.63 is elevated, but the negative enterprise value distorts standard multiples.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Aspire Biopharma Holdings, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →